NeuroGuard Psilocybin Trial Preventing mushroom

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

⏱ 2 min read🗓 Reviewed Nov 14, 2026🔬 AI-researched · Reviewed by Nathan Peters · How we grade the evidence

Bottom line: A Phase 2 trial is exploring whether psilocybin may help prevent or reduce chemo-induced neuropathy in cancer patients.

A new Phase 2 trial is exploring whether psilocybin — the active compound in magic mushrooms — could help prevent or reduce the long-term nerve damage caused by chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN) causes tingling, numbness, and pain in the hands and feet, and can significantly impact a cancer patient’s quality of life for months or even years after treatment ends.

NeuroGuard Psilocybin Trial Preventing mushroom
Original art — ShroomWire

What’s being tested

The trial is comparing psilocybin to a placebo and to standard supportive care. It aims to determine whether the psychedelic compound can prevent or reduce the severity of CIPN. Researchers are looking for measurable changes in symptoms and overall function. If successful, this could offer a new option for managing a condition that affects many cancer survivors.

The design at a glance

The trial is sponsored by M.D. Anderson Cancer Center. It is not yet recruiting participants. Phase 2 studies like this one are designed to test whether an intervention works in a larger group of people, while also continuing to monitor its safety.

Three groups will be involved: one will receive psilocybin, another will get standard supportive care, and the third will receive a placebo. This setup allows for a direct comparison of outcomes across the groups.

Why it matters

If the trial shows that psilocybin can prevent or reduce CIPN, it could be a new tool for managing a condition that lingers long after chemotherapy ends. This could help patients maintain their independence and reduce the strain on healthcare systems. Psilocybin’s potential for treating neuropathic pain has also drawn interest in its use for other neurological conditions.

What this does NOT mean yet

This trial is still in the planning or recruitment phase. It has not yet produced results. Registration on a clinical trial registry does not confirm that the treatment is effective, safe, or endorsed by medical professionals. Many trials do not reach their goals. The outcomes of this study will only be known once the trial is complete and the data is analyzed.

How to follow it

For updates, check the ClinicalTrials.gov record. This page will show the trial’s progress, including recruitment status, participant numbers, and any published results.

Sources

https://clinicaltrials.gov/study/NCT07227909 | NCT07227909

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Frequently asked questions

Is psilocybin being tested for chemotherapy-induced neuropathy?
Yes, a Phase 2 trial is exploring whether psilocybin may help prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
What is the design of the psilocybin trial for CIPN?
The trial is comparing psilocybin to a placebo and to standard supportive care. It aims to determine whether psilocybin can prevent or reduce the severity of CIPN.
What are the potential benefits of psilocybin for CIPN?
If successful, psilocybin could offer a new option for managing CIPN, which can significantly impact a cancer patient’s quality of life for months or even years after treatment ends.
What should readers know about the current status of the psilocybin trial?
The trial is still in the planning or recruitment phase and has not yet produced results. Registration on a clinical trial registry does not confirm that the treatment is effective or safe.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *